| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424046000 | Powder or dust containing | 29 |
| 20080226564 | Respiratory dispersion for metered dose inhalers - A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures. | 09-18-2008 |
| 20080260657 | Process for Milling Poorly Soluble Drugs in Presence of Liquid Propellants - Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant. | 10-23-2008 |
| 20080292562 | Medicaments For Inhalation Comprising Pde IV Inhibitors and Enantiomerically Pure Glycopyrrolate Salts - The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors (2) and salts of formula (1) wherein X may have the meanings defined in the description and claims, and their use in the treatment of respiratory complaints. | 11-27-2008 |
| 20090022671 | TREATMENT METHODS - Disclosed are methods of treating rhinosinusitis of the upper airway passages in patients afflicted with said disease, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of mometasone furoate as a monotherapy effective for treating said disease. | 01-22-2009 |
| 20090104127 | SUSPENSION AEROSOL FORMULATIONS OF PHARMACEUTICAL PRODUCTS - Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME. | 04-23-2009 |
| 20090110647 | METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1 - A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system. | 04-30-2009 |
| 20090238772 | METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF RSV INFECTION - Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. The siRNA comprises a sense strand of ALN-RSV01 and an antisense strand of ALN-RSV01. | 09-24-2009 |
| 20090291050 | PARTICULATE MATERIALS - Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles or formulations. In one embodiment, an inhaler contains an aerosol formulation containing a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm. The particles may be suspended in a nonsolvent hydrofluorocarbon fluid vehicle (e.g., HFA 134a or 227ea) at a concentration within a range from about 0.2% w/v to about 5% w/v. The formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the vehicle. The particulate active substance may contain salmeterol xinafoate, budesonide, salbutamol sulfate, dihydroergotamine mesylate, risperidone-(9-hydroxy)-palmitate, bromocriptine mesylate, or derivatives thereof. In some examples, the active substance is dihydroergotamine mesylate. | 11-26-2009 |
| 20090324512 | POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 12-31-2009 |
| 20100028269 | DRY POWDER FORMULATIONS - A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes. | 02-04-2010 |
| 20100055049 | INSULIN DERIVATIVE FORMULATIONS FOR PULMONARY DELIVERY - Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent. | 03-04-2010 |
| 20100124536 | Hemophilia Treatment by Inhalation of Coagulation Factors - Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μm or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale. | 05-20-2010 |
| 20100143268 | Formulations for Delivery Via Pressurised Metered Dose Inhalers Comprising an Essential Oil as Suspension Stabiliser - A formulation suitable for delivery from a pressurised metered dose inhaler comprises a hydrofluoroalkane liquid, which is pharmaceutically acceptable, for instance HFA 134a or HFA 227, a drug to be delivered to the lung which is insoluble in the hydrofluoroalkane, the drug being in particulate form in the composition, further containing a suspension stabiliser which is a non-toxic essential oil miscible with the hydrofluoroalkane liquid at room temperature. The essential oil is preferably one having some amphiphilic property, such as a ketone or aldehyde compound. Insulin may be formulated for inhalation. | 06-10-2010 |
| 20100143269 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA - Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate and processes for preparing the same. | 06-10-2010 |
| 20100215590 | Micronization Method - The invention relates to a method for producing a micronized, virtually anhydrous form of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 | 08-26-2010 |
| 20100247450 | USE OF ERYTHROPOIETIN - The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells. | 09-30-2010 |
| 20100247451 | USE OF ERYTHROPOIETIN - The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells. | 09-30-2010 |
| 20100247452 | USE OF ERYTHROPOIETIN - The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells. | 09-30-2010 |
| 20100284940 | METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE - Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C | 11-11-2010 |
| 20100329999 | Antiperspirant Aerosol Composition - According to a first aspect, antiperspirant aerosol compositions are disclosed comprising antiperspirant active particulates, a propellant and at least 5% by weight of the entire antiperspirant aerosol composition of a silicone component, wherein (a) the antiperspirant active particulates are the only particulates in the antiperspirant aerosol composition; (b) the silicone component comprises one or more silicones and the or each silicone is a non-volatile silicone. According to a second aspect, packaged antiperspirant aerosol compositions according to the first aspect are disclosed. | 12-30-2010 |
| 20110027193 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS - Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM). | 02-03-2011 |
| 20110097281 | FOAM SKIN CARE CREAM - The present invention relates to a formulation comprising an aqueous emulsion and a blowing agent for a foaming skin cream, a distinctive feature thereof being that the emulsion comprises microsilver. | 04-28-2011 |
| 20110097282 | New Use For Budesonide and Formoterol - The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease. | 04-28-2011 |
| 20120039818 | ANTI-CHAFING AEROSOL POWDER - A composition and method which prevents or mitigates irritation on the skin of a subject by protecting against or relieving chafing, itching and moisture, and which provides a cooling sensation where applied. | 02-16-2012 |
| 20140322142 | PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND - A stable crystalline micronized particulate of a glycopyrronium salt may be prepared by suspending the drug in a water-immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage. | 10-30-2014 |
| 20140377190 | COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS - Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. | 12-25-2014 |
| 20150139917 | AEROSOL DEVICE BASED ON SEBUM-ABSORBING POWDER AND A PARTICULAR WATER-INSOLUBLE MINERAL COMPOUND - The invention relates to an aerosol device which contains a cosmetic composition comprising: (i) one or more sebum-absorbing powders with a sebum uptake of greater than or equal to 35 ml/100 g, (ii) a water-insoluble mineral compound which is calcium carbonate, (iii) one or more C | 05-21-2015 |
| 20150353666 | POLYMERS POLYMERIZED FROM AT LEAST FOUR MONOMERS, AND COMPOSITIONS AND USES THEREOF - Family of non-homopolymers synthesized from N-vinyl lactam, (meth)acrylic acid, hydrophobic (meth)acrylic ester of a straightchain or branched-chain alkyl alcohol and monomer selected from the group consisting of functionalized and unfunctionalized: dialkyl maleates, dialkyl fumarates, and combinations thereof. The non-homopolymers may exhibit solubility in one or more lower molecular weight alcohols and/or a glass transition temperature greater than 80° C. | 12-10-2015 |
| 20160045406 | METHOD FOR THE MANUFACTURE OF ANHYDROUS COSMETIC COMPOSITIONS - A method of manufacture of an anhydrous cosmetic composition comprising the mixing of dried calcium chloride with liquid carrier material and fragrance comprising a solvent to give a give a base composition, followed by the gassing of the base composition with a propellant to give an aerosol composition, wherein the fragrance and the solvent therein are pre-mixed and this mixture comprises one or more components having a log P of greater than 5.5 and a vapour pressure at 25° C. of less than 0.001 mm Hg (0.1333 Pa) and does not comprise dipropyleneglycol at 3% or greater of this mixture; the method enhancing the homogeneity and stability of the composition. | 02-18-2016 |
